EVFM Evofem Biosciences, Inc.
Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.
Company profile
Ticker
EVFM
Exchange
Website
CEO
Saundra L. Pelletier
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Neothetics, Inc.
SEC CIK
Corporate docs
Investment data
Securities sold
Number of investors
Calendar
6 May 20
27 May 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Net income | -19.15M | -12.72M | -13.8M | -35.45M | |
| Diluted EPS | -0.4 | -0.27 | -0.3 | -0.97 | |
| Operating income | -19.24M | -12.87M | -14.3M | -11.94M | |
| Net change in cash | -6.79M | -16.55M | -18.58M | 50.5M | |
| Cash on hand | 8.79M | 15.57M | 32.12M | 50.7M |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Net income | -80.03M | -125.71M | -105.31M | -13.02M | |
| Diluted EPS | -1.99 | -5.74 | -55.78 | -5.66 | |
| Operating income | -52.74M | -77.64M | -35.69M | -12.04M | |
| Net change in cash | 14.24M | 119K | -10.27M | -26.27M | |
| Cash on hand | 15.57M | 1.33M | 1.21M | 11.48M |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 22 May 20 | Fitzpatrick Alexander A | Common Stock | Payment of exercise | Dispose F | 4.99 | 39,487 | 197.04K | 166,042 |
| 22 May 20 | Culwell Kelly | Common Stock | Payment of exercise | Dispose F | 4.99 | 39,435 | 196.78K | 146,999 |
| 22 May 20 | File Justin J. | Common Stock | Payment of exercise | Dispose F | 4.99 | 42,262 | 210.89K | 280,415 |
| 22 May 20 | Pelletier Saundra L | Common Stock | Payment of exercise | Dispose F | 4.99 | 84,525 | 421.78K | 564,705 |
| 22 May 20 | Barrans Russell | Common Stock | Payment of exercise | Dispose F | 4.99 | 19,474 | 97.18K | 308,964 |
Institutional ownership Q1 2020
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Risks
- Our financial condition, clinical development efforts, and results of operations could be adversely affected by the ongoing coronavirus outbreak.
- Anti-takeover provisions in our stockholder rights plan could make a third-party acquisition of us difficult.
Management Discussion
- Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.
- We are a San Diego-based clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. We exist to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). Our lead Multipurpose Vaginal pH Regulator (MVP-RTM) product candidate, Phexxi (L-lactic acid, citric acid, and potassium bitartrate), is in development for multiple potential indications: prevention of pregnancy, prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) in women and prevention of urogenital transmission of Neisseria gonorrhoeae infection (gonorrhea) in women.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. senior Avg
|
|
New words:
accessibility, acquisition, acute, advertising, afflicted, agent, alternate, alternative, altogether, anniversary, ATM, attempt, attention, avoid, Baker, beneficial, beneficially, Black, blocker, buy, call, callable, cGMP, China, clearance, cloud, communication, conditionally, confidence, contact, copy, cyber, delay, delivered, delivery, deploy, discontinue, discouraging, disease, disruption, distancing, diversion, domestic, DPT, duration, economic, encourage, enthusiastic, entry, evolving, expenditure, failure, feet, fleet, FM, focused, foregoing, foreign, forfeited, furlough, globe, good, greater, greatly, highly, holder, home, hospital, important, imposed, inconsistent, inspection, interrupt, interruption, issuable, large, led, Lessee, lessor, linked, local, located, location, lower, lowest, LP, manner, Master, Merton, minimize, mirroring, missed, moved, multiplied, national, Nationally, negotiate, Notwithstanding, null, outbreak, outlook, ownership, pandemic, passed, passing, PDUFA, Phexxi, PhexxiTM, Philadelphia, Piper, power, precautionary, presence, preservation, prioritization, prolonged, prospective, purport, raw, reached, regional, rely, remedy, remotely, rentable, respiratory, rest, Sandler, senior, serialization, shipping, situation, slowdown, small, social, software, spread, square, staffing, strain, successor, surfaced, syndrome, takeover, temporarily, tender, tenure, thereof, threat, Threshold, training, transport, Trust, type, uncertain, unexpected, unexpectedly, unfavorable, unforeseen, unsolicited, void, voided, volume, VWAP, workplace, worsen, Wuhan
Removed:
absence, acceleration, achieved, acquiree, acquirer, adjusted, advantage, America, American, applied, applying, approach, approximated, attributable, audit, authorization, awarded, bear, bifurcation, blank, building, BV, campaign, cancel, carefully, Carlo, Certified, Codification, combined, comparative, comply, consisted, contra, CRO, deducting, defer, derivative, detail, differentiate, diminishing, discretionary, dose, Dutch, effected, effecting, EGC, embedded, emerging, ENA, enrolled, envision, EP, EVFM, Evolution, exist, exit, exited, extinguishment, footnote, formulation, fourth, generating, Guide, highest, hindsight, hybrid, identifiable, imputed, inactive, Institute, instrument, invoiced, IPO, iv, judgment, Jumpstart, label, launched, left, legacy, liquidation, LLC, marketability, matured, measure, method, mid, modify, Monte, nature, Network, noncontrolling, North, obligor, officially, opening, overallotment, package, participated, partnership, permitted, Pharma, Practice, preference, PWERM, recapitalization, recasting, reclassified, redeemable, redemption, referenced, registration, reliably, repaid, represented, restatement, resubmit, retained, retrospective, revalued, revised, RSU, sensitive, sensitivity, side, simulation, SPA, split, sponsor, sponsorship, STI, study, successive, symbol, ticker, traded, transferable, transition, treatment, Tryst, twelve, underwriter, underwritten, unexercised, unrelated, valuation, WCGT
Financial reports
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
1 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
14 May 18
10-K
2017 FY
Annual report
26 Feb 18
Current reports
8-K
Other Events
22 May 20
8-K
Departure of Directors or Certain Officers
12 May 20
8-K
Evofem Biosciences Reports First Quarter 2020 Financial Results
6 May 20
8-K
Evofem Biosciences to Report First Quarter 2020 Results and Update on Financing and Commercial Launch Plans
28 Apr 20
8-K
Evofem Biosciences Secures up to $25 Million in Convertible Note Financing
27 Apr 20
8-K
Entry into a Material Definitive Agreement
17 Apr 20
8-K
Evofem Biosciences Adopts Shareholder Rights Agreement
25 Mar 20
8-K
Evofem Biosciences Reports Fourth Quarter and Year-end 2019
12 Mar 20
8-K
Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick, M.D., to its Board of Directors
26 Feb 20
8-K
Regulation FD Disclosure
10 Jan 20
Registration and prospectus
424B3
Prospectus supplement
18 May 20
424B3
Prospectus supplement
18 May 20
S-8
Registration of securities for employees
13 May 20
D
$25M in debt / options / securities to be acquired, sold $15M, 2 investors
6 May 20
8-A12B
Registration of securities on exchange
25 Mar 20
S-8
Registration of securities for employees
12 Mar 20
S-8
Registration of securities for employees
12 Mar 20
S-3
Shelf registration
18 Nov 19
424B3
Prospectus supplement
2 Jul 19
RW
Registration withdrawal request
24 Jun 19
Proxies
DEF 14A
Definitive proxy
8 May 20
DEFA14A
Additional proxy soliciting materials
1 May 20
PRE 14A
Preliminary proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Mar 20
DEF 14A
Definitive proxy
30 Mar 20
DEFR14A
Revised proxy
10 May 19
DEF 14A
Definitive proxy
24 Apr 19
PRE 14A
Preliminary proxy
12 Apr 19
DEF 14A
Definitive proxy
21 Mar 18
DEFA14A
Additional proxy soliciting materials
21 Mar 18
Other
EFFECT
Notice of effectiveness
3 Dec 19
EFFECT
Notice of effectiveness
3 Jul 19
EFFECT
Notice of effectiveness
8 May 19
CORRESP
Correspondence with SEC
3 May 19
UPLOAD
Letter from SEC
3 May 19
EFFECT
Notice of effectiveness
22 May 18
CORRESP
Correspondence with SEC
17 May 18
CORRESP
Correspondence with SEC
17 May 18
UPLOAD
Letter from SEC
17 May 18
EFFECT
Notice of effectiveness
2 May 18
Ownership
4
Evofem Biosciences / SAUNDRA L PELLETIER ownership change
26 May 20
4
Evofem Biosciences / Alexander A Fitzpatrick ownership change
26 May 20
4
Evofem Biosciences / Kelly Culwell ownership change
26 May 20
4
Evofem Biosciences / Russell Barrans ownership change
26 May 20
4
Evofem Biosciences / Justin J. File ownership change
26 May 20
4
Change in insider ownership
26 May 20
SC 13D/A
Evofem Biosciences / PDL BIOPHARMA ownership change
26 May 20
4
Evofem Biosciences / Colin Rutherford ownership change
13 May 20
4
Evofem Biosciences / Anthony Stephen O'Brien ownership change
13 May 20
4
Evofem Biosciences / Gillian Greer ownership change
13 May 20
Patents
APP
Utility
Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides
14 May 20
The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides.
GRANT
Utility
Compositions and methods for enhancing the efficacy of contraceptive microbicides
25 Feb 20
The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides.